Loading clinical trials...
Loading clinical trials...
An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Characterize the Impact of the Cytochrome P450 3A Inhibitor Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Subjects
Conditions
Interventions
Dazucorilant
Itraconazole
Locations
1
United States
Site 01
Baltimore, Maryland, United States
Start Date
May 31, 2024
Primary Completion Date
August 2, 2024
Completion Date
August 2, 2024
Last Updated
July 1, 2025
NCT07473570
NCT07227259
NCT06815991
NCT07305753
NCT07291336
NCT06011018
Lead Sponsor
Corcept Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions